TRUGOLF ANNOUNCES NEWLY EXPANDED AI TECHNOLOGY LICENSING AGREEMENT WITH MLSPATIAL
March 20, 2024 09:00 ET | TruGolf Holdings, Inc.
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (Nasdaq: TRUG) ("TruGolf”), among the leading sellers and distributors of golf simulator software and hardware, today...
Arcutis logo.png
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
February 28, 2024 16:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
TH_logo_couleur.png
Triple Hair Group Signs Licensing Agreement for South Korean Market with Mother’s Pharmaceutical
October 17, 2023 07:30 ET | Triple Hair Inc.
Licensing agreement grants Mother’s Pharmaceutical exclusive rights to sell Triple Hair’s Therapy-07 prescription drug in South Korea.Agreement valued at US$5.75 million in upfront and milestone...
TH_logo_couleur.png
Triple Hair Group signe une entente de licence avec Mother's Pharmaceutical pour le marché sud-coréen
October 17, 2023 07:30 ET | Triple Hair Inc.
L'entente de licence accorde à Mother's Pharmaceutical les droits exclusifs de vente du médicament sur ordonnance Thérapie-07 de Triple Hair en Corée du Sud.L'entente est évaluée à 5,75 M$ US en...
Crossject signs new
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023 10:55 ET | CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand  Exclusive licensing, distribution and...
Crossject signe un n
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
July 20, 2023 10:55 ET | CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
logo1.png
Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
July 20, 2023 01:30 ET | CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
logo1.png
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023 01:30 ET | CROSSJECT
Press Release Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand  Exclusive licensing, distribution and...
PSI_Prof. Roger Schibli
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
April 27, 2023 05:00 ET | ITM Isotope Technologies Munich SE
Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM...
Flora Craft Brands Announces Exclusive Licensing Agreement with Athlete Activist led Cannabis Brand Revenant in Illinois
Flora Craft Brands Announces Exclusive Licensing Agreement with Athlete Activist led Cannabis Brand Revenant in Illinois
March 15, 2023 10:46 ET | Flora Craft Brands
Downers Grove, IL, March 15, 2023 (GLOBE NEWSWIRE) -- Flora Craft Brands, a licensed craft grow 2108010130-CG in Elgin, Illinois is proud to announce an exclusive licensing agreement with Revenant,...